GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amarin Corp PLC (NAS:AMRN) » Definitions » Cyclically Adjusted PS Ratio

Amarin (Amarin) Cyclically Adjusted PS Ratio : 0.87 (As of Apr. 27, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Amarin Cyclically Adjusted PS Ratio?

As of today (2024-04-27), Amarin's current share price is $0.8749. Amarin's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $1.01. Amarin's Cyclically Adjusted PS Ratio for today is 0.87.

The historical rank and industry rank for Amarin's Cyclically Adjusted PS Ratio or its related term are showing as below:

AMRN' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.62   Med: 7.04   Max: 47.65
Current: 0.86

During the past years, Amarin's highest Cyclically Adjusted PS Ratio was 47.65. The lowest was 0.62. And the median was 7.04.

AMRN's Cyclically Adjusted PS Ratio is ranked better than
74.32% of 736 companies
in the Drug Manufacturers industry
Industry Median: 2.06 vs AMRN: 0.86

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Amarin's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.183. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.01 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Amarin Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Amarin's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amarin Cyclically Adjusted PS Ratio Chart

Amarin Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.27 6.74 3.99 1.32 0.86

Amarin Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.32 1.57 1.21 0.92 0.86

Competitive Comparison of Amarin's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Amarin's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amarin's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amarin's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Amarin's Cyclically Adjusted PS Ratio falls into.



Amarin Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Amarin's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.8749/1.01
=0.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amarin's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Amarin's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.183/120.1096*120.1096
=0.183

Current CPI (Dec. 2023) = 120.1096.

Amarin Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.063 100.573 0.075
201406 0.061 100.773 0.073
201409 0.081 100.474 0.097
201412 0.094 99.576 0.113
201503 0.091 99.975 0.109
201506 0.098 100.573 0.117
201509 0.117 100.274 0.140
201512 0.145 99.676 0.175
201603 0.139 99.676 0.167
201606 0.179 101.072 0.213
201609 0.157 100.274 0.188
201612 0.144 99.676 0.174
201703 0.128 100.374 0.153
201706 0.167 100.673 0.199
201709 0.175 100.474 0.209
201712 0.199 100.075 0.239
201803 0.154 100.573 0.184
201806 0.179 101.072 0.213
201809 0.187 101.371 0.222
201812 0.246 100.773 0.293
201903 0.223 101.670 0.263
201906 0.305 102.168 0.359
201909 0.320 102.268 0.376
201912 0.399 102.068 0.470
202003 0.429 102.367 0.503
202006 0.339 101.769 0.400
202009 0.402 101.072 0.478
202012 0.428 101.072 0.509
202103 0.360 102.367 0.422
202106 0.385 103.364 0.447
202109 0.358 104.859 0.410
202112 0.342 106.653 0.385
202203 0.238 109.245 0.262
202206 0.237 112.734 0.253
202209 0.222 113.431 0.235
202212 0.223 115.425 0.232
202303 0.212 117.618 0.216
202306 0.197 119.611 0.198
202309 0.162 120.708 0.161
202312 0.183 120.110 0.183

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Amarin  (NAS:AMRN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Amarin Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Amarin's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Amarin (Amarin) Business Description

Traded in Other Exchanges
Address
112-114 St Stephens Green, Iconic Offices, The Greenway, Block C Ardilaun Court, Dublin, IRL, D02 TD28
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its lead product includes Vascepa.
Executives
Steven B Ketchum officer: Chief Scientific Officer 2483 EAST BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
Patrick Holt director, officer: See Remarks C/O AMARIN CORPORATION, SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2 L2 D02 VK60
Oliver O'connor director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Paul Cohen director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Diane E. Sullivan director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Louis Iii Sterling director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Keith Horn director 204 STATE ROUTE 17B, P.O. BOX 5013, C/O MONTICELLO CASINO AND RACEWAY, MONTICELLO NY 12701
Patrice Eadon Bonfiglio director 488 HAVILAND ROAD, STAMFORD CT 06903
Mark Dipaolo director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Thomas Charles Reilly officer: SVP and CFO C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Aaron Berg officer: EVP, President US C/O AMARIN PHARMA, INC., 1430 ROUTE 206, BEDMINSTER NJ 07921
Karim Mikhail director, officer: President and CEO C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER NJ 08807
Olsen Per Wold director C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Murray Stewart director C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3